Last reviewed · How we verify
NCT04553549
Safety and Feasibility of the Infinity Catheter for Radial Access
trial testing Transradial approach in Brain Tumor in 80 participants. Completed in 30 October 2022.
15 September 2022
Quick facts
| Lead sponsor | Rutgers, The State University of New Jersey |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 October 2020 |
| Primary completion | 15 September 2022 |
| Estimated completion | 30 October 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Transradial approach
Conditions studied
- Brain Tumor — all drugs for Brain Tumor →
- Stroke, Acute — all drugs for Stroke, Acute →
- Brain Aneurysm — all drugs for Brain Aneurysm →
- Intracranial Arteriovenous Malformations — all drugs for Intracranial Arteriovenous Malformations →
Sponsor
Rutgers, The State University of New Jersey
Who can join
18 and older, any sex, with Brain Tumor or Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this single arm study is to evaluate the safety and feasibility of the AXS Infinity LS (Stryker, Freemont, CA, USA) and AXS Infinity LS Plus (Stryker, Freemont, CA, USA) catheters during the transradial approach through a secondary use of the data collected during neurointerventional procedures. This includes evaluating the conversion rates to a transfemoral approach. A secondary aim of the study is to assess the radial artery occlusion rates post procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04553549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Brain Tumor
Currently open trials in the same condition.
- NCT07224503 — C-SMART vs BE Well for Patients With Brain Tumors · NA · recruiting
- NCT07323966 — Feasibility of Mask-Free Radiotherapy for Brain Tumor Patients · NA · recruiting
- NCT07122752 — Feasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy · active not recruiting
- NCT07105358 — Visual Plasticity Following Brain Lesions · NA · recruiting
- NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
Other Rutgers, The State University of New Jersey trials
Trials by the same sponsor.
- NCT07243886 — Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD) · NA · not yet recruiting
- NCT06955130 — Lactate and Glycerol Contribution to Gluconeogenesis · NA · not yet recruiting
- NCT06822010 — SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma · Phase 2 · not yet recruiting
- NCT07525011 — Comparative Study of Denture Fabrication Techniques · NA · not yet recruiting
- NCT06834204 — Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04553549 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rutgers, The State University of New Jersey
- Last refreshed: 11 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04553549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing